Healthcare
Fulgent Genetics, Inc.(FLGT)
Live Price
Offline$18.00
+1.69% today
1Y Change
-8.16%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $440.00M
- Revenue Growth
- +13.8%
- EPS Growth
- -39.7%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fulgent Genetics, Inc. (FLGT) is a Healthcare stock with a market cap of $440.00M and listed on NASDAQ. The stock last traded around $18.00 and down 8.2% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +13.8%, EPS growth of -39.7%, a dividend yield of 0.0%. What stands out right now is revenue +13.8%, EPS -39.7%, free cash flow -545.1% with operating margin -33.1% and ROIC -9.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FLGT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.8% vs +7.6% peer median
Operating Margin
Below sector median
-33.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 1, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +13.8% and EPS is at -39.7%, with operating margin around -33.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 1, 2026 | โ | +7.0% | +13.0% | +28.0% |
2026 Feb 27, 2026 | +433.3% | -7.4% | -4.6% | +1.7% |
2025 Nov 7, 2025 | +158.3% | +3.0% | +10.4% | +5.7% |
Benchmark Edge
FLGT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FLGT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FLGT Max Drawdown
-55.30%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FLGT and SPY.
Company Overview
Fulgent Genetics, Inc.
NASDAQ Global Market
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
- Leadership
- Ming Hsieh
- IPO Date
- Sep 29, 2016
- Employees
- 1.3k
- Street Address
- 4978 Santa Anita Avenue
- Mailing
- El Monte, CA, 91780
- Region
- El Monte, CA, US
- Reporting Currency
- USD
- Investor Line
- 626 350 0537
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.4
- Price/Book
- 0.4
Growth
- Revenue
- +13.8%
- EPS
- -39.7%
- Free Cash Flow
- -545.1%
Profitability
- Gross Margin
- 38.1%
- Operating Margin
- -33.1%
- Net Margin
- -23.0%
- ROE
- -6.7%
- ROIC
- -9.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 5.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.